TORONTO, Canada I March 7, 2016 I Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) has received approval from Health Canada to conduct a Phase 2 trial of its lead drug, ATB-346, in patients with osteoarthritis of the knee. The primary endpoints of the study will be clinical assessments of pain and inflammation over the course of 10 days of treatment with ATB-346 at 250 mg once daily. Analysis of blood samples from Antibe’s Phase 1 clinical study strongly suggested that ATB-346 is considerably more potent and long-lasting than had been predicted from studies in animals. The Phase 2 study is expected to begin in March, and will be performed by Toronto-based Topstone Research. Daniel Legault, Antibe’s CEO, remarked: “Receiving Health Canada’s approval to move forward in the development of ATB-346 is a significant milestone for Antibe. The study should be started within the next few weeks, with completion expected in mid-summer.“
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (Citagenix), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry. Citagenix Inc. is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
SOURCE: Antibe Therapeutics
Post Views: 71
TORONTO, Canada I March 7, 2016 I Antibe Therapeutics Inc. (“Antibe”) (TSXV:ATE, OTCQX:ATBPF) has received approval from Health Canada to conduct a Phase 2 trial of its lead drug, ATB-346, in patients with osteoarthritis of the knee. The primary endpoints of the study will be clinical assessments of pain and inflammation over the course of 10 days of treatment with ATB-346 at 250 mg once daily. Analysis of blood samples from Antibe’s Phase 1 clinical study strongly suggested that ATB-346 is considerably more potent and long-lasting than had been predicted from studies in animals. The Phase 2 study is expected to begin in March, and will be performed by Toronto-based Topstone Research. Daniel Legault, Antibe’s CEO, remarked: “Receiving Health Canada’s approval to move forward in the development of ATB-346 is a significant milestone for Antibe. The study should be started within the next few weeks, with completion expected in mid-summer.“
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.
Antibe’s subsidiary, Citagenix Inc. (Citagenix), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry. Citagenix Inc. is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.
SOURCE: Antibe Therapeutics
Post Views: 71
